ArticleGenes & development2018
Pivotal role of NAMPT in the switch of melanoma cells toward an invasive and drug-resistant phenotype.
Open access · diamondAbstract read
In one paragraph
Article in Genes & development, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 98 citations in OpenAlex.
- MITF-Driven melanoma plasticity as a core mechanism of therapy resistance: integrating microenvironmental signaling, mechanotransduction, and metabolic reprogramming.Cell cycle (Georgetown, Tex.) · 2026Review
- CagA promotes gastric cancer stemness and metastasis via DNMT1-mediated epigenetic silencing of BEX1.Cancer gene therapy · 2026Article
- Bi-directional regulation between NAD/NAMPT and IFN-γ/PD-L1 axes via BRD4/IRF1 and mitochondrial respiration in metastatic cutaneous melanoma.Journal of experimental & clinical cancer research : CR · 2026Article
- Crosstalk BetweenCancers · 2026Review
- RAS/PI3K pathway mutations sensitise epithelial ovarian cancer cells to a PARP/NAMPT inhibitor combination.Communications biology · 2025Article
- SETDB1 is critically required for uveal melanoma growth and represents a promising therapeutic target.Cell death & disease · 2025Article
- NAMPT and NNMT released via extracellular vesicles and as soluble mediators are distinguished traits of BRAF inhibitor resistance of melanoma cells impacting on the tumor microenvironment.Cell communication and signaling : CCS · 2025Article
- STAT5 Is Necessary for the Metabolic Switch Induced by IL-2 in Cervical Cancer Cell Line SiHa.International journal of molecular sciences · 2024Article
- RICTOR/mTORC2 downregulation in BRAFMolecular cancer · 2024Article
- LKB1-SIK2 loss drives uveal melanoma proliferation and hypersensitivity to SLC8A1 and ROS inhibition.EMBO molecular medicine · 2023Article
- DNMT3A mutation promotes leukemia development through NAM-NAD metabolic reprogramming.Journal of translational medicine · 2023Article
- The journey from melanocytes to melanoma.Nature reviews. Cancer · 2023Review
- STAT proteins in cancer: orchestration of metabolism.Nature reviews. Cancer · 2023Review
- Interferon Gamma-Inducible NAMPT in Melanoma Cells Serves as a Mechanism of Resistance to Enhance Tumor Growth.Cancers · 2023Article
- Targeting NADFrontiers in immunology · 2023Review
- Crosstalk between metabolic reprogramming and epigenetics in cancer: updates on mechanisms and therapeutic opportunities.Cancer communications (London, England) · 2022Review
- NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic Targets.International journal of molecular sciences · 2022Review
- Review
- The Kynurenine Pathway and Cancer: Why Keep It Simple When You Can Make It Complicated.Cancers · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Mickaël OhannaU1065, Institut National de la Santé et de la Recherche Médicale (INSERM), Biology and Pathologies of Melanocytes, Equipe Labellisée L'Association pour la Recherche sur le Cancer (ARC) 2015, Université Nice Côte d'Azur, INSERM, Centre Méditerranéen de Médecine Moléculaire (C3M), 06204 Nice, France.
Mickaël CerezoU1065, Institut National de la Santé et de la Recherche Médicale (INSERM), Biology and Pathologies of Melanocytes, Equipe Labellisée L'Association pour la Recherche sur le Cancer (ARC) 2015, Université Nice Côte d'Azur, INSERM, Centre Méditerranéen de Médecine Moléculaire (C3M), 06204 Nice, France.
Nicolas NottetUniversité Nice Côte d'Azur, INSERM, C3M, 06204 Nice, France.
Karine BilleU1065, Institut National de la Santé et de la Recherche Médicale (INSERM), Biology and Pathologies of Melanocytes, Equipe Labellisée L'Association pour la Recherche sur le Cancer (ARC) 2015, Université Nice Côte d'Azur, INSERM, Centre Méditerranéen de Médecine Moléculaire (C3M), 06204 Nice, France.
Robin DidierU1065, Institut National de la Santé et de la Recherche Médicale (INSERM), Biology and Pathologies of Melanocytes, Equipe Labellisée L'Association pour la Recherche sur le Cancer (ARC) 2015, Université Nice Côte d'Azur, INSERM, Centre Méditerranéen de Médecine Moléculaire (C3M), 06204 Nice, France.
Guillaume BerangerU1065, Institut National de la Santé et de la Recherche Médicale (INSERM), Biology and Pathologies of Melanocytes, Equipe Labellisée L'Association pour la Recherche sur le Cancer (ARC) 2015, Université Nice Côte d'Azur, INSERM, Centre Méditerranéen de Médecine Moléculaire (C3M), 06204 Nice, France.
Baharia MograbiU1081, INSERM, Institute of Research on Cancer and Ageing of Nice (IRCAN), Equipe Labellisée ARC, Université Nice Côte d'Azur, UMR7284, Centre National de la Recherche Scientifique (CNRS), 06107 Nice, France.
Stéphane RocchiU1065, Institut National de la Santé et de la Recherche Médicale (INSERM), Biology and Pathologies of Melanocytes, Equipe Labellisée L'Association pour la Recherche sur le Cancer (ARC) 2015, Université Nice Côte d'Azur, INSERM, Centre Méditerranéen de Médecine Moléculaire (C3M), 06204 Nice, France.
Laurent Yvan-CharvetU1065, INSERM, Team ATIP-Avenir, Université Nice Côte d'Azur, INSERM, C3M, 06204 Nice, France.
Robert Ballotti *U1065, Institut National de la Santé et de la Recherche Médicale (INSERM), Biology and Pathologies of Melanocytes, Equipe Labellisée L'Association pour la Recherche sur le Cancer (ARC) 2015, Université Nice Côte d'Azur, INSERM, Centre Méditerranéen de Médecine Moléculaire (C3M), 06204 Nice, France.
Corine Bertolotto *U1065, Institut National de la Santé et de la Recherche Médicale (INSERM), Biology and Pathologies of Melanocytes, Equipe Labellisée L'Association pour la Recherche sur le Cancer (ARC) 2015, Université Nice Côte d'Azur, INSERM, Centre Méditerranéen de Médecine Moléculaire (C3M), 06204 Nice, France.
Inserm · FRCentre Méditerranéen de Médecine Moléculaire · FRCentre National de la Recherche Scientifique · FR
Funding
No grant is acknowledged in the PubMed record.
Abstract
In BRAF
Indexed as
AnimalsCell Line, TumorCell ProliferationCytokinesDrug Resistance, NeoplasmEnzyme ActivationEnzyme InhibitorsFemaleGene Expression Regulation, NeoplasticHumansIndolesMelanomaMetabolomeMiceMice, NudeNADBRAF protein, humanCytokinesEnzyme InhibitorsIndolesNADNicotinamide Phosphoribosyltransferasenicotinamide phosphoribosyltransferase, humanProto-Oncogene Proteins B-rafSTAT5 Transcription FactorSulfonamidesVemurafenibmelanomametabolismNADtargeted therapy
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.